Compare RXO & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RXO | ERAS |
|---|---|---|
| Founded | 2022 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.0B |
| IPO Year | 2022 | 2021 |
| Metric | RXO | ERAS |
|---|---|---|
| Price | $23.45 | $18.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 12 |
| Target Price | ★ $16.33 | $14.25 |
| AVG Volume (30 Days) | 2.1M | ★ 3.7M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.81 | 36.23 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,742,000,000.00 | N/A |
| Revenue This Year | $0.49 | N/A |
| Revenue Next Year | $6.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.20 | N/A |
| 52 Week Low | $10.43 | $1.33 |
| 52 Week High | $29.90 | $24.28 |
| Indicator | RXO | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 49.12 | 50.90 |
| Support Level | $11.40 | $17.36 |
| Resistance Level | $29.46 | $19.96 |
| Average True Range (ATR) | 1.44 | 1.02 |
| MACD | 0.20 | -0.16 |
| Stochastic Oscillator | 90.56 | 53.27 |
RXO Inc is a brokered transportation platform defined by technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.